How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Digitally enabled therapies for adults with anxiety disorders: early value assessment

    Closed for comments This consultation ended on at   Request commenting lead permission

    GID-MT589 anxiety disorders draft guidance v0.8 FINAL_CLEAN [noACIC].docx

    Early value assessment (EVA) guidance rapidly provides recommendations on promising health technologies that have the potential to address national unmet need. NICE has assessed early evidence on these technologies to determine if earlier patient and system access in the NHS is appropriate while further evidence is generated.

    The medical technology advisory committee has considered the evidence and the views of clinical and patient experts. This topic is one of the pilots using the new EVA approach. EVA guidance recommendations are conditional while more evidence is generated to address uncertainty in their evidence base. Although there are uncertainties, they do not suggest a risk to patient safety. NICE has included advice in this guidance on how to minimise any clinical or system risk of early access to treatment.

    Further evidence will be generated within the next 3 years to assess if the benefits of these technologies are realised in practice. NICE guidance will be reviewed to include this evidence and any new research and make a recommendation on the routine adoption of these technologies across the NHS.

    This document has been prepared for public consultation. It summarises the evidence and views that have been considered and sets out the evidence generation recommendations made by the committee. NICE invites comments from registered stakeholders, healthcare professionals and the public. This document should be read along with the evidence for this EVA (an EVA report, cost and resource use report).

    The advisory committee is interested in receiving comments on the following:

    • Has all the relevant evidence been considered?

    • Are the summaries of clinical effectiveness, costs and resource use reasonable interpretations of the evidence?

    • Are the recommendations sound and a suitable basis for EVA guidance to the NHS?

    Equality issues

    NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the recommendations may need changing to meet these aims. In particular, please tell us if the recommendations:

    • could have a different effect on people protected by the equality legislation than on the wider population, for example by making it more difficult in practice for a specific group to access the technology

    • could have any adverse effect on people with a particular disability or disabilities.

    Please provide any relevant information or data you have about such effects and how they could be avoided or reduced.

    Note that this document is not NICE's final guidance on digitally enabled therapies for adults with anxiety disorders. The conditional recommendations in section 1 and the accompanying points on evidence generation in section 4 may change after consultation.

    After consultation, NICE will consider the comments received. The final recommendations will be the basis for NICE's EVA guidance on using the technologies with evidence generation.

    Key dates:

    Closing date for comments: 15 March 2023